Systems Approach to targeted and long-acting HIV/AIDS therapy

Drug Delivery and Translational Research

Volumn 5, Issue 6, 2015, Pages 531-539

  Ho, Rodney J Y ^a   Yu, Jesse ^a   Li, Bowen ^a   Kraft, John C ^a   Freeling, Jennifer P ^a   Koehn, Josefin ^a   Shao, Jingwei ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

HIV; Long acting; Lymphatic drug insufficiency; Systems approach; Targeted drug delivery

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; INDINAVIR; NANOPARTICLE; ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; BLOOD; CD4+ T LYMPHOCYTE; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG TARGETING; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE; LYMPH NODE CELL; LYMPHATIC SYSTEM; LYMPHOID CELL; LYMPHOID TISSUE; MONONUCLEAR CELL; NANOMEDICINE; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; T CELL DEPLETION; VIRUS REPLICATION; ACQUIRED IMMUNODEFICIENCY SYNDROME; COMBINATION DRUG THERAPY; DRUG POTENTIATION; HIV INFECTIONS; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ANTI-RETROVIRAL AGENTS; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; NANOMEDICINE;

EID: 84946151661     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-015-0254-y     Document Type: Review

References (22)

1. Ho RJY, Gibaldi M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs. 2nd ed. Hoboken: Wiley-Blackwell; 2013.
2. Qin C et al. Therapeutic target database update 2014: a resource for targeted therapeutics. Nucleic Acids Res. 2014;42:D1118–1123. doi:10.1093/nar/gkt1129.
3. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–5. doi:10.1038/nrd1470.
4. Butler J et al. Improving cardiovascular clinical trials conduct in the United States: recommendation from clinicians, researchers, sponsors, and regulators. Am Heart J. 2015;169:305–14. doi:10.1016/j.ahj.2014.12.001.
5. Liu Z et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83–92.
6. Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science. 1990;249:1533–44.
7. Castagna A et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS. 2006;20:795–803. doi:10.1097/01.aids.0000218542.08845.b2.
8. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med. 2004;350:1023–35. doi:10.1056/NEJMra025195.
9. Montaner JS et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia Canada: a population-based study. Lancet. 2010;376:532–9. doi:10.1016/S0140-6736(10)60936-1.
10. Harrigan PR, Whaley M, Montaner JS. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS. 1999;13:F59–62.
11. Kinman L et al. Optimization of lipid-indinavir complexes for localization in lymphoid tissues of HIV-infected macaques. J Acquir Immune Defic Syndr. 2006;42:155–61. doi:10.1097/01.qai.0000214822.33905.87.
12. Fletcher CV et al. Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A. 2014;111:2307–12. doi:10.1073/pnas.1318249111.
13. Schacker T et al. Rapid accumulation of human immunodeficiency virus (HIV) in lymphatic tissue reservoirs during acute and early HIV infection: implications for timing of antiretroviral therapy. J Infect Dis. 2000;181:354–7. doi:10.1086/315178.
14. Zhang Y, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet. 2001;40:159–68. doi:10.2165/00003088-200140030-00002.
15. Trainor GL. The importance of plasma protein binding in drug discovery. Expert Opin Drug Discovery. 2007;2:51–64. doi:10.1517/17460441.2.1.51.
16. Hall HI et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173:1337–44. doi:10.1001/jamainternmed.2013.6841.
17. Kinman L et al. Lipid-drug association enhanced HIV-1 protease inhibitor indinavir localization in lymphoid tissues and viral load reduction: a proof of concept study in HIV-2287-infected macaques. J Acquir Immune Defic Syndr. 2003;34:387–97.
18. Koehn J, Ho RJ. Novel liquid chromatography-tandem mass spectrometry method for simultaneous detection of anti-HIV drugs lopinavir, ritonavir, and tenofovir in plasma. Antimicrob Agents Chemother. 2014;58:2675–80. doi:10.1128/AAC.02748-13.
19. Piliero PJ. Pharmacokinetic properties of nucleoside/nucleotide reverse transcriptase inhibitors. J Acquir Immune Defic Syndr. 2004;37 Suppl 1:S2–S12.
20. Freeling JP, Koehn J, Shu C, Sun J, Ho RJ. Anti-HIV drug-combination nanoparticles enhance plasma drug exposure duration as well as triple-drug combination levels in cells within lymph nodes and blood in primates. AIDS Res Hum Retrovir. 2014. doi:10.1089/aid.2014.0210.
21. Oussoren C, Zuidema J. Crommelin, D. J. & Storm, G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim Biophys Acta. 1997;1328:261–72.
22. Alberts B. Molecular biology of the cell. 4th ed. Science: Garland; 2002.